Floatz logo

TAK228

Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic

M.D. Anderson Cancer CenterPhase 1Dormant
CC
40/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
25/ 100
Competitive Position
95/ 100

Competitive context

117 Active assets in the Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic cohort.

Asset / SponsorPhaseRating
Fludarabine
National Cancer Institute (NCI)
Phase 3BB
FILGRASTIM
St. Jude Children's Research Hospital
Phase 2BB
Pegloticase
M.D. Anderson Cancer Center
Phase 4BB
Rasburicase
M.D. Anderson Cancer Center
Phase 4BB
Fludarabine
National Cancer Institute (NCI)
Phase 3BB

View all 50 →

Same molecule, other indications

TAK228 is also rated in:

ovarian carcinosarcomaDormant
CCC
Indicative ·
48 / 100
View asset →
ovarian neoplasmDormant
CCC
Indicative ·
48 / 100
View asset →
ovarian serous adenocarcinomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →